Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

Trial statusAvailable

Trial phaseNot listed

Trial typeExpanded Access

Biological sexAll

Age18+

SponsorStemCyte, Inc.

About this trial

REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.

Male or female aged ≥ 18

With post-COVID condition

Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)

Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE

Neurological disorders prior to COVID-19 diagnosis

With pre-existing terminal illness

With known immune disease

Is pregnant or breastfeeding

No treatment groups listed

StemCyte, Inc.

Lead sponsor